An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

AM-679 (part of the AM cannabinoid series) is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5 nM at CB1 and 49.5 nM at CB2. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB1 agonists AM-694 and AM-2233, and the selective CB2 agonist AM-1241. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.

Property Value
dbo:abstract
  • AM-679 (part of the AM cannabinoid series) is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5 nM at CB1 and 49.5 nM at CB2. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB1 agonists AM-694 and AM-2233, and the selective CB2 agonist AM-1241. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole. (en)
dbo:casNumber
  • 335160-91-3
dbo:fdaUniiCode
  • 61TFT4BO1C
dbo:thumbnail
dbo:wikiPageID
  • 30449731 (xsd:integer)
dbo:wikiPageLength
  • 3795 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1086383330 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 20 (xsd:integer)
dbp:casNumber
  • 335160 (xsd:integer)
dbp:chemspiderid
  • 25991468 (xsd:integer)
dbp:h
  • 20 (xsd:integer)
dbp:i
  • 1 (xsd:integer)
dbp:iupacName
  • methanone (en)
dbp:legalCa
  • Schedule II (en)
dbp:legalDe
  • NpSG (en)
dbp:legalUk
  • Class B (en)
dbp:n
  • 1 (xsd:integer)
dbp:o
  • 1 (xsd:integer)
dbp:smiles
  • Ic1ccccc1Cccn3CCCCC (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • GAJBHYUAJOTAEW-UHFFFAOYSA-N (en)
dbp:unii
  • 61 (xsd:integer)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 451565677 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:width
  • 200 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • AM-679 (part of the AM cannabinoid series) is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5 nM at CB1 and 49.5 nM at CB2. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB1 agonists AM-694 and AM-2233, and the selective CB2 agonist AM-1241. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole. (en)
rdfs:label
  • AM-679 (cannabinoid) (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License